Milgamma 100 (Benfotiamine, Pyridoxine Hydrochloride)

Benfotiamine is a lipid‑soluble prodrug of thiamine that easily crosses cell membranes. Inside cells it is converted to thiamine diphosphate, a co‑factor for enzymes involved in glucose metabolism. This helps reduce the formation of harmful advanced glycation end‑products and supports normal nerve function.

The appropriate dose of Milgamma 100 is determined by a qualified healthcare professional based on the individual’s clinical condition, age, and overall health. Patients should follow the prescribing clinician’s instructions and not exceed the recommended amount.

Safety data for Milgamma 100 in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk, and after consultation with a physician. Breastfeeding mothers should also seek medical advice before starting the supplement.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Milgamma 100 combines benfotiamine, a highly bioavailable thiamine prodrug, with pyridoxine hydrochloride. Compared with standard thiamine salts, benfotiamine achieves higher intracellular levels, potentially offering greater metabolic benefits. The product also provides a balanced B6 dose, making it a convenient single‑tablet option for nerve‑support nutrition.

Milgamma 100 should be stored at ambient temperature below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Milgamma 100 is taken orally, usually with water. The tablet should be swallowed whole and not chewed or crushed unless directed otherwise by a healthcare professional. It can be taken with or without food, depending on the prescriber’s advice.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and significant liver enzyme elevations. Patients should discontinue use and seek immediate medical attention if they experience symptoms like rash, swelling, difficulty breathing, or jaundice.

Individuals with known hypersensitivity to benfotiamine, thiamine, pyridoxine, or any excipients in the tablet should not use Milgamma 100. Those with severe renal impairment or who are pregnant or breastfeeding should only use it after a thorough risk‑benefit assessment by a qualified clinician.